United States - English - NLM (National Library of Medicine)

corepharma, llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - methenamine hippurate tablets, usp are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets, usp and other antibacterial drugs, methenamine hippurate tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets, usp are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methe

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - methenamine hippurate tablets usp are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets usp and other antibacterial drugs, methenamine hippurate tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.

United States - English - NLM (National Library of Medicine)

county line pharmaceuticals, llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. it should not be used

United States - English - NLM (National Library of Medicine)

alvogen inc. - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. it should not be used

United States - English - NLM (National Library of Medicine)

carilion materials management - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - methenamine hippurate tablets, usp are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets, usp and other antibacterial drugs, methenamine hippurate tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets, usp are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methe

United States - English - NLM (National Library of Medicine)

winthrop u.s. - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - methenamine hippurate is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets usp is contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to

United States - English - NLM (National Library of Medicine)

leading pharma, llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g - methenamine hippurate is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when longterm therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets usp is contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate tablets, usp are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets, usp and other antibacterial drugs, methenamine hippurate tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets, usp are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methe

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should n

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - methenamine hippurate - oral tablet - 1gram